Extracellular matrix components in breast cancer progression and metastasis.

The extracellular matrix (ECM) is composed of highly variable and dynamic components that regulate cell behavior. The protein composition and physical properties of the ECM govern cell fate through biochemical and biomechanical mechanisms. This requires a carefully orchestrated and thorough regulation considering that a disturbed ECM can have serious consequences and lead to pathological conditions like cancer. In breast cancer, many ECM proteins are significantly deregulated and specific matrix components promote tumor progression and metastatic spread. Intriguingly, several ECM proteins that are associated with breast cancer development, overlap substantially with a group of ECM proteins induced during the state of tissue remodeling such as mammary gland involution. Fibrillar collagens, fibronectin, hyaluronan and matricellular proteins are matrix components that are common to both involution and cancer. Moreover, some of these proteins have in recent years been identified as important constituents of metastatic niches in breast cancer. In addition, specific ECM molecules, their receptors or enzymatic modifiers are significantly involved in resistance to therapeutic intervention. Further analysis of these ECM proteins and the downstream ECM mediated signaling pathways may provide a range of possibilities to identify druggable targets against advanced breast cancer.

[1]  S. Ghatak,et al.  Regulation of MDR1 Expression and Drug Resistance by a Positive Feedback Loop Involving Hyaluronan, Phosphoinositide 3-Kinase, and ErbB2*♦ , 2005, Journal of Biological Chemistry.

[2]  Lilly Y. W. Bourguignon,et al.  Signaling Properties of Hyaluronan Receptors* , 2002, The Journal of Biological Chemistry.

[3]  M J Bissell,et al.  Involvement of extracellular matrix constituents in breast cancer. , 1995, Seminars in cancer biology.

[4]  H. Moch,et al.  Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update , 2011, Virchows Archiv.

[5]  Li Yang,et al.  Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells. , 2011, Molecular medicine reports.

[6]  J. Pringle,et al.  Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms , 2009, Breast Cancer Research.

[7]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[8]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[9]  I. Kii,et al.  Interaction between Periostin and BMP-1 Promotes Proteolytic Activation of Lysyl Oxidase* , 2010, The Journal of Biological Chemistry.

[10]  O. Vasiljeva,et al.  Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. , 2006, Cancer research.

[11]  K. Hansen,et al.  Rat mammary extracellular matrix composition and response to ibuprofen treatment during postpartum involution by differential GeLC-MS/MS analysis. , 2012, Journal of proteome research.

[12]  J. Muschler,et al.  Cell-matrix interactions in mammary gland development and breast cancer. , 2010, Cold Spring Harbor perspectives in biology.

[13]  M. C. Ling,et al.  Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells , 1999, Oncogene.

[14]  T. Sørlie,et al.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome , 2008, The Journal of pathology.

[15]  A. Oates,et al.  The identification of metastasis-related gene products in a rodent mammary tumour model. , 1996, Biochemical Society transactions.

[16]  M. Waltham,et al.  Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. , 2005, Cancer research.

[17]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[18]  N. Ishiguro,et al.  Inhibition of hyaluronan synthesis in breast cancer cells by 4‐methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo , 2012, International journal of cancer.

[19]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[20]  N. Tan,et al.  Matricellular Proteins: A Sticky Affair with Cancers , 2012, Journal of oncology.

[21]  Elizabeth R. Smith,et al.  Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells , 2000, Oncogene.

[22]  C. Streuli,et al.  Extracellular matrix controls insulin signaling in mammary epithelial cells through the RhoA/Rok pathway , 2009, Journal of cellular physiology.

[23]  Philip M. Carpenter,et al.  Laminin 332 Expression in Breast Carcinoma , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[24]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[25]  J. Wang-Rodriguez,et al.  Motility Induction in Breast Carcinoma by Mammary Epithelial Laminin 332 (Laminin 5) , 2009, Molecular Cancer Research.

[26]  N. Hynes,et al.  Ablation of β1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation , 2005, The Journal of cell biology.

[27]  L. Cai,et al.  Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. , 2011, Cancer biotherapy & radiopharmaceuticals.

[28]  N. Cho,et al.  Invasive breast cancer induces laminin-332 upregulation and integrin β4 neoexpression in myofibroblasts to confer an anoikis-resistant phenotype during tissue remodeling , 2012, Breast Cancer Research.

[29]  D. Berger,et al.  Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. , 1997, Surgery.

[30]  H. Tamaki,et al.  Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  G. Tuszynski,et al.  Plasma thrombospondin levels in patients with gynecologic malignancies , 1994, Cancer.

[32]  Mina J Bissell,et al.  Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. , 2010, Journal of cell science.

[33]  P. Clézardin,et al.  Human breast tumors override the antiangiogenic effect of stromal thrombospondin‐1 in vivo , 2005, International journal of cancer.

[34]  R. Khokha,et al.  Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution , 2003, The Journal of cell biology.

[35]  V. Bramwell,et al.  Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[36]  J. Noti Adherence to osteopontin via alphavbeta3 suppresses phorbol ester-mediated apoptosis in MCF-7 breast cancer cells that overexpress protein kinase C-alpha. , 2000, International journal of oncology.

[37]  C. Watson,et al.  Stat5 as a Target for Regulation by Extracellular Matrix (*) , 1995, The Journal of Biological Chemistry.

[38]  H. Nevanlinna,et al.  Tenascin-C expression in invasion border of early breast cancer — A predictor of local and distant recurrence , 1998 .

[39]  A. Mannermaa,et al.  Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer , 2013, International journal of cancer.

[40]  T. Sakakura,et al.  Involvement of large tenascin-C splice variants in breast cancer progression. , 2003, The American journal of pathology.

[41]  Jean-Michel,et al.  SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. , 1998, Cancer research.

[42]  H. Moon,et al.  Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. , 2001, Cancer research.

[43]  M. Kusakabe,et al.  Tenascin in breast cancer development--is epithelial tenascin a marker for poor prognosis? , 1995, Cancer letters.

[44]  Mina J. Bissell,et al.  The Hyaluronan Receptors CD44 and Rhamm (CD168) Form Complexes with ERK1,2 That Sustain High Basal Motility in Breast Cancer Cells* , 2007, Journal of Biological Chemistry.

[45]  Y. Taniyama,et al.  Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. , 2011, International journal of molecular medicine.

[46]  S. Ghatak,et al.  Regulation of Multidrug Resistance in Cancer Cells by Hyaluronan* , 2003, Journal of Biological Chemistry.

[47]  J. Graham,et al.  Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. , 1997, European journal of cancer.

[48]  R. Chiquet‐Ehrismann,et al.  Tenascin-C induced signaling in cancer. , 2006, Cancer letters.

[49]  Edi Brogi,et al.  Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs , 2011, Nature Medicine.

[50]  P. Schedin Pregnancy-associated breast cancer and metastasis , 2006, Nature Reviews Cancer.

[51]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[52]  Bonnie F. Sloane,et al.  Cathepsin B inhibition limits bone metastasis in breast cancer. , 2012, Cancer research.

[53]  A. El-Karef,et al.  Co‐stimulation of human breast cancer cells with transforming growth factor‐β and tenascin‐C enhances matrix metalloproteinase‐9 expression and cancer cell invasion , 2004, International journal of experimental pathology.

[54]  S. Ménard,et al.  Regulation of breast cancer response to chemotherapy by fibulin-1. , 2007, Cancer research.

[55]  M. Watabe,et al.  Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. , 2012, Cancer research.

[56]  M. Loda,et al.  Elevated Serum Periostin Levels in Patients with Bone Metastases from Breast but not Lung Cancer , 2003, Breast Cancer Research and Treatment.

[57]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[58]  C H Streuli,et al.  Laminin mediates tissue-specific gene expression in mammary epithelia , 1995, The Journal of cell biology.

[59]  H. Rodemann,et al.  Fibronectin and laminin increase resistance to ionizing radiation and the cytotoxic drug Ukrain® in human tumour and normal cells in vitro , 2003, International journal of radiation biology.

[60]  R. Weinberg,et al.  Systemic Endocrine Instigation of Indolent Tumor Growth Requires Osteopontin , 2008, Cell.

[61]  R. Samant,et al.  Osteopontin: an effector and an effect of tumor metastasis. , 2010, Current molecular medicine.

[62]  Robin L. Anderson,et al.  Integrin‐dependent response to laminin‐511 regulates breast tumor cell invasion and metastasis , 2012, International journal of cancer.

[63]  J. Rubin,et al.  sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration. , 2011, Archives of biochemistry and biophysics.

[64]  Kevin W Eliceiri,et al.  Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2 , 2011, Nature Medicine.

[65]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[66]  M. Del Vecchio,et al.  Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. , 2004, Endocrine-related cancer.

[67]  H. Rui,et al.  Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence , 2010, Cancer biology & therapy.

[68]  T. Stein,et al.  Microenvironment of the Involuting Mammary Gland Mediates Mammary Cancer Progression , 2007, Journal of Mammary Gland Biology and Neoplasia.

[69]  R. Moll,et al.  Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast , 2005, Virchows Archiv.

[70]  M. Hemler,et al.  Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. , 2010, Cancer Research.

[71]  A. Jensen,et al.  The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. , 2010, Clinical breast cancer.

[72]  D. Neri,et al.  Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy , 2008, Clinical Cancer Research.

[73]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[74]  J. Erler,et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.

[75]  J. Lawler,et al.  The effect of thrombospondin-1 on breast cancer metastasis , 2009, Breast Cancer Research and Treatment.

[76]  Kornelia Polyak,et al.  Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer , 2010, Clinical Cancer Research.

[77]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[78]  Hamid Morjani,et al.  Extracellular Matrix Proteins Modulate Antimigratory and Apoptotic Effects of Doxorubicin , 2012, Chemotherapy research and practice.

[79]  S. Sleijfer,et al.  Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response , 2008, Clinical Cancer Research.

[80]  S. Kumar,et al.  Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. , 2007, International journal of oncology.

[81]  T. Nishiyama,et al.  Incorporation of Tenascin-C into the Extracellular Matrix by Periostin Underlies an Extracellular Meshwork Architecture* , 2009, The Journal of Biological Chemistry.

[82]  J. Foidart,et al.  MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis , 2012, Oncogene.

[83]  Meenakshi Singh,et al.  Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. , 2006, The American journal of pathology.

[84]  P. Schedin,et al.  Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. , 2000, Cancer research.

[85]  L. Gutierrez,et al.  Thrombospondin-1: Multiple Paths to Inflammation , 2011, Mediators of inflammation.

[86]  P. Heldin,et al.  Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells , 2007, International journal of cancer.

[87]  Matthew J. Paszek,et al.  Balancing forces: architectural control of mechanotransduction , 2011, Nature Reviews Molecular Cell Biology.

[88]  F. O'Malley,et al.  Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[89]  V. Borges,et al.  Epithelial and Mesenchymal Cell Biology Alternatively Activated Macrophages and Collagen Remodeling Characterize the Postpartum Involuting Mammary Gland across Species , 2010 .

[90]  L. Hennighausen,et al.  Regulation of Mammary Differentiation by Extracellular Matrix Involves Protein-tyrosine Phosphatases* , 1998, The Journal of Biological Chemistry.

[91]  Hanna Y. Irie,et al.  Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment , 2009, Nature.

[92]  David Cameron,et al.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.

[93]  Wolfhard Semmler,et al.  Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE‐MRI in a longitudinal in vivo study , 2011, International journal of cancer.

[94]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[95]  Y. Hsiao,et al.  SPARC (Osteonectin) in Breast Tumors of Different Histologic Types and Its Role in the Outcome of Invasive Ductal Carcinoma , 2010, The breast journal.

[96]  T. Oskarsson,et al.  Extracellular matrix players in metastatic niches , 2012, The EMBO journal.

[97]  F. O'Malley,et al.  Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. , 1997, Archives of pathology & laboratory medicine.

[98]  V. Castronovo,et al.  A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.

[99]  J. F. Harris,et al.  Osteopontin expression in a group of lymph node negative breast cancer patients , 1998, International journal of cancer.

[100]  Hong Peng,et al.  Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.

[101]  D. Noh,et al.  Comparative profiling of plasma proteome from breast cancer patients reveals thrombospondin-1 and BRWD3 as serological biomarkers , 2011, Experimental & Molecular Medicine.

[102]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[103]  Bonnie F. Sloane,et al.  Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion , 2011, Breast Cancer Research.